- Home
- BYAH vs PPCB Comparison
BYAH vs PPCB Comparison
Compare BYAH & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYAH | PPCB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.6M |
| IPO Year | 2023 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BYAH | PPCB |
|---|---|---|
| Price | $2.60 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 827.0K | ★ 3.2M |
| Earning Date | 03-02-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.06 |
| 52 Week High | $6.64 | $6.79 |
Technical Indicators
Market Signals| Indicator | BYAH | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 44.71 |
| Support Level | $2.58 | $0.90 |
| Resistance Level | $2.77 | $1.38 |
| Average True Range (ATR) | 0.25 | 0.29 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 5.43 | 1.59 |
Price Performance
Historical ComparisonAbout BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.